Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (6): 1566-1573.doi: 10.13481/j.1671-587X.20220623
• Research in clinical medicine • Previous Articles Next Articles
Hong GAO,Li LIN,Xiaohong YAN,Ping TAO,Youzhu LI()
Received:
2022-04-27
Online:
2022-11-28
Published:
2022-12-07
Contact:
Youzhu LI
E-mail:232398106@qq.com
CLC Number:
Hong GAO,Li LIN,Xiaohong YAN,Ping TAO,Youzhu LI. Effect of transient prematur of luteinizing hormone in gonadotropin releasing hormone antagonist flexible protocols on pregnancy outcomes of patients underwent fresh IVF/ICSI-ET cycles[J].Journal of Jilin University(Medicine Edition), 2022, 48(6): 1566-1573.
Tab.1
Basic informations of patients in two groups"
Group | n | Age (year) | Duration of infertility(year) | BMI(kg·m-2) | AMH[ρB/(g·L-1)] | Basic FSH [λB/(IU·L-1)] | |
---|---|---|---|---|---|---|---|
Non-tansient premature of LH | 105 | 32.4±4.8 | 2(1,4) | 21.69±2.02 | 2.34(1.36,3.84) | 7.43±2.52 | |
Tansient premature of LH | 40 | 33.2±5.6 | 2.5(1.5,4) | 22.64±3.73 | 2.93(1.47,5.80) | 7.46±3.80 | |
t/Z/χ2 | -0.864 | -0.793 | -0.297 | -1.163 | -0.058 | ||
P | 0.389 | 0.427 | 0.686 | 0.245 | 0.954 | ||
Group | n | Basic LH [λB/(IU·L-1)] | Basic E2[ρB/(ng·L-1)] | No.ofAFC | Percentage of poorovary reserve(η/%) | Percentage of PCOS(η/%) | |
Non-tansient premature of LH | 105 | 4.41±2.16 | 51.92±18.07 | 11.9±6.7 | 27(25.7) | 10(9.5) | |
Tansient premature of LH | 40 | 5.07±1.94 | 52.26±17.97 | 13.6±9.0 | 10(25) | 7(17.5) | |
t/Z/χ2 | -1.694 | -0.102 | -1.090 | 0.008 | 1.781 | ||
P | 0.092 | 0.919 | 0.280 | 0.930 | 0.182 |
Tab.2
Clinical indexes of ovarian stimulation of patients in two groups"
Group | n | Gn duration untill antagonist starting day(t/d) | E2 level on antagonist use day E2[ρB/(pg·L-1)] | D level on antagonist use day P[ρB/(μg·L-1)] | Dominant follicle diameter on antagonistuse day (l/mm) | Antagonist use duration (t/d) |
---|---|---|---|---|---|---|
Non-tansient premature of LH | 105 | 6.62±1.39 | 0.92±0.57 | 0.64±0.42 | 13.83±1.75 | 4.42±1.53 |
Tansient premature of LH | 40 | 7.49±1.34 | 1.40±0.86 | 0.75±0.44 | 13.98±1.63 | 3.78±0.92 |
t | -3.251 | -3.233 | -1.424 | -0.443 | 3.090 | |
P | 0.001 | 0.002 | 0.157 | 0.658 | 0.003 | |
Group | n | Gn use dosage(IU) | Gn use duration(t/d) | E2 level on hCGinjection day [ρB/(pg·L-1)] | P level on hCG injection day [ρB/(μg·L-1)] | Endometrial thickness on hCG injection day(l/mm) |
Non-tansient premature of LH | 105 | 1 822.93±590.77 | 9.3±1.8 | 2.61±1.34 | 0.73±0.37 | 11.22±2.53 |
Tansient premature of LH | 40 | 1 954.69±582.15 | 9.5±1.4 | 3.12±1.54 | 0.73±0.38 | 11.70±2.49 |
t | -1.213 | -0.521 | -1.972 | 0.120 | -1.025 | |
P | 0.229 | 0.603 | 0.051 | 0.905 | 0.307 |
Tab.3
Outcome indexes of ovarian stimulation of patients in two groups"
Group | n | No. of available oocytes | No. of MⅡ oocytes | No. of 2PN | No.of D3 available embryos | No.of D3 high-quality embryos |
---|---|---|---|---|---|---|
Non-tansient premature of LH | 105 | 9.2±5.1 | 7.7±4.1 | 6.3±3.7 | 4.8±3.3 | 3.9±3.0 |
Tansient premature of LH | 40 | 10.3±6.1 | 8.5±5.0 | 6.8±4.3 | 5.2±3.6 | 3.9±3.4 |
t/χ2 | -1.086 | -0.943 | -0.604 | -0.564 | -0.020 | |
P | 0.279 | 0.348 | 0.547 | 0.575 | 0.984 | |
Group | n | Mature oocytes [n(η/%)] | Normal fertilization [n(η/%)] | Available embryos[n(η/%)] | High-quality embryos[n(η/%)] | |
Non-tansient premature of LH | 105 | 804(83.6) | 666(82.8) | 507(76.1) | 407(61.1) | |
Tansient premature of LH | 40 | 340(82.9) | 271(79.7) | 208(76.8) | 157(57.9) | |
t/χ2 | 0.087 | 1.580 | 0.042 | 0.812 | ||
P | 0.768 | 0.209 | 0.838 | 0.368 |
Tab.4
Indexes of pregnancy outcomes of patients underwent fresh IVF/ICSI-ET cycle transplantation in two groups"
Group | n | No.of transferred embryos | Transferred blastocysts[n(η/%)] | Implanted embryos[n(η/%)] | Clinical pregnancy[n(η/%)] | Ongoing pregnancy [n(η/%)] |
---|---|---|---|---|---|---|
Non-tansient premature of LH | 105 | 2(1,2) | 33(31.4) | 68(42.0) | 60(57.1) | 51(48.6) |
Tansient premature of LH | 40 | 1.5(1,2) | 12(30.0) | 22(36.7) | 19(47.5) | 15(37.5) |
Z/χ2 | -0.355 | 0.028 | 0.512 | 1.086 | 1.432 | |
P | 0.245 | 0.868 | 0.474 | 0.297 | 0.231 |
Tab.6
Multivariate Logistic regression analysis on transient premature of LH in GnRH antagonist flexible protocol"
Feature | B value | Standard error of B value | OR(95%CI) | χ2 | P |
---|---|---|---|---|---|
Basic LH(IU·L-1) | 0.176 | 0.091 | 1.193(0.999-1.425) | 3.783 | 0.052 |
Gn duration untill antagonist starting day(d) | 0.416 | 0.151 | 1.516(1.128-2.038) | 7.588 | 0.006 |
E2 level on antagonist use day (pg·L-1) | 0.885 | 0.301 | 2.424(1.345-4.371) | 8.670 | 0.003 |
1 | DOVEY S, MCINTYRE K, JACOBSON D, et al. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles[J]. Fertil Steril, 2011, 96(3): 585-589. |
2 | BOSCH E, VALENCIA I, ESCUDERO E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome[J]. Fertil Steril,2003,80(6): 1444-1449. |
3 | ZHANG D D, ZHANG D, SUN Z Y, et al. The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol[J]. Gynecol Endocrinol, 2020, 36(6): 550-553. |
4 | 中国女医师协会生殖医学专业委员会专家共识编写组, 李 蓉, 甄秀梅, 等. 辅助生殖领域拮抗剂方案标准化应用专家共识[J].中华生殖与避孕杂志,2022(2): 109-116. |
5 | ALPHA Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul Consensus Workshop on Embryo Assessment: Proceedings of an expert meeting[J]. Hum Reprod, 2011, 26(6): 1270-1283. |
6 | BARRI P N, COROLEU B, MARTINEZ F, et al. Stimulation protocols for poor responders and aged women[J]. Mol Cell Endocrinol, 2000, 166(1): 15-20. |
7 | XIONG Y J, WANG J Z, LIU L, et al. Effects of high progesterone level on the day of human chorionic gonadotrophin administration in in vitro fertilization cycles on epigenetic modification of endometrium in the peri-implantation period[J]. Fertil Steril, 2017,108(2): 269-276. |
8 | FANG Y Y, WU Q J, ZHANG T N, et al. Assessment of the development of assisted reproductive technology in Liaoning Province of China, from 2012 to 2016[J]. BMC Health Serv Res, 2018, 18(1): 873. |
9 | WANG M, XI Q S, YANG Q Y, et al. The relationship between a novel evaluation parameter of premature luteinization and IVF outcomes[J]. Reprod Biomed Online, 2021, 42(2): 323-331. |
10 | 肖 珊, 莫美兰, 刘 苏, 等. 多囊卵巢综合征患者拮抗剂方案中早发LH升高对IVF-ET临床结局的影响[J]. 生殖医学杂志, 2022, 31(1): 6-12. |
11 | 叶 虹. 再论促黄体生成素峰[J]. 生殖医学杂志, 2010, 19(S1): 3-5. |
12 | FOROOZANFARD F, MORAVEJI S A, TAGHAVI S A,et al. Association between serum estradiol level on the day of hCG administration and IVF-ICSI outcome[J]. J Obstet Gynaecol India, 2016, 66(3): 170-173. |
13 | LUO X, PEI L, LI F J, et al. Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial[J]. BMC Pregnancy Childbirth, 2021, 21(1): 348. |
14 | DEPALO R, TREROTOLI P, CHINCOLI A, et al. Endogenous luteinizing hormone concentration and IVF outcome during ovarian stimulation in fixed versus flexible GnRH antagonist protocols: an RCT[J]. Int J Reprod Biomed, 2018, 16(3): 175-182. |
15 | 罗克莉, 郭 慧, 龚 斐. 提早加用促性腺激素释放激素拮抗剂可改善低反应患者的助孕效果[J]. 实用医学杂志, 2012, 28(13): 2211-2213. |
16 | BONDUELLE M, OBERYÉ J, MANNAERTS B,et al.Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation[J]. Hum Reprod, 2010, 25(6): 1433-1440. |
17 | FLUKER M, GRIFO J, LEADER A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation[J]. Fertil Steril, 2001, 75(1): 38-45. |
18 | 王泽华, 王艳丽. 妇产科学[M]. 8版. 北京: 人民卫生出版社, 2019: 70. |
19 | 梁晓燕,方丛,黄睿,等.辅助生殖技术实践与提高[M].北京:人民卫生出版社,2018:151. |
20 | SHIN J J, PARK K E, CHOI Y M, et al. Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: a preliminary randomized trial[J].Clin Exp Reprod Med,2018,45(3): 135-142. |
21 | CHEN Y, YE B L, YANG X J, et al. Predicting the outcome of different protocols of in vitro fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome[J].J Int Med Res, 2017,45(3): 1138-1147. |
22 | HAMDINE O, BROEKMANS F J, EIJKEMANS M J C,et al. Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6[J]. Fertil Steril, 2013, 100(3): 867-874. |
23 | LIN L T, WANG P H, TSUI K H. Early initiation of GnRH antagonist administration in a flexible protocol: is it better? [J]. J Chin Med Assoc, 2018, 81(1): 4-6. |
24 | WERTHEIMER A, DANIELI-GRUBER S, HOCHBERG A, et al. The association between treatment parameters on the day of gonadotropin-releasing hormone antagonist initiation during a flexible protocol and oocyte maturation rate[J]. Reprod Biol, 2020, 20(2): 127-131. |
25 | KOCHHAR P K, GHOSH P. Diminished ovarian reserve predisposes to premature luteinizing hormone surges in gonadotropin-releasing hormone antagonist cycles in in vitro fertilization[J]. J Hum Reprod Sci, 2020, 13(3): 191-195. |
26 | MESSINIS I E, MESSINI C I, ANIFANDIS G, et al. Gonadotropin surge-attenuating factor: a nonsteroidal ovarian hormone controlling GnRH-induced LH secretion in the normal menstrual cycle[J]. Vitam Horm, 2018, 107: 263-286. |
|